TABLE 3.
Difference of second outcomes between the two groups.
| Variable | Group RR (n = 73) | Group DR (n = 73) | p-Value |
|---|---|---|---|
| Time metrics | |||
| Onset time (min) | 13.22 ± 1.70 | 15.12 ± 2.07* | 0.001 |
| Procedure time (min) | 18.12 ± 3.32 | 18.42 ± 3.00 | 0.566 |
| Time to fully alert (min) | 2.52 ± 1.11 | 3.62 ± 1.28* | 0.001 |
| Time to hospital discharge (min) | 18.58 ± 2.98 | 21.21 ± 3.60* | 0.001 |
| Intubating conditions, n (%) | 0.945 | ||
| Excellent | 22 (30.14%) | 23 (31.51%) | |
| Good | 42 (57.53%) | 40 (54.79%) | |
| Poor | 9 (12.33%) | 10 (13.70%) | |
| Lowest oxygen saturation (%) | 88.22 ± 2.16 | 89.90 ± 2.03 | 0.061 |
| Severity of coughing, n (0/1/2/3) | 2/13/44/14 | 4/15/36/18 | 0.572 |
| Incidence of dreaming, n (%) | 26 (35.62%) | 30 (41.10%) | 0.496 |
| Satisfaction of patients | 8.82 ± 0.71 | 8.66 ± 0.63 | 0.142 |
| Satisfaction of bronchoscopist | 9.00 (9.00–9.00) | 9.00 (8.00–9.00) | 0.072 |
| Consumption of fentanyl (µg) | 79.16 ± 17.20 | 81.26 ± 22.21 | 0.525 |
| Consumption of remifentanil (µg) | 134.45 ± 21.15 | 134.73 ± 19.74 | 0.934 |
| Consumption of remimazolam tosilate (mg) | 19.71 (18.36–21.29) | — | |
| Consumption of dexmedetomidine (µg) | — | 43.15 (40.12–45.24) | |
| Number of remedies lidocaine, n (%) | 14 (19.18%) | 14 (19.18%) | 1.000 |
| Number of remedies midazolam, n (%) | 26 (35.62%) | 25 (34.25%) | 0.863 |
| Number of remedies propofol, n (%) | 4 (5.48%) | 6 (8.22%) | 0.745 |
| Number of vasoactive drugs, n (%) | 16 (21.92%) | 20 (27.40%) | 0.565 |
| Willing to the repeat bronchoscopy, n (%) | 60 (82.19%) | 58 (79.45%) | 0.834 |
Variables presented as mean ± SD, median (interquartile range) or number of patients n (%).*p < 0.05 vs. Group RR.